Redesigning CAR therapy to tackle immune effector cell-associated hematotoxicity
Abstract Although recognized, the field has yet to fully explore the mechanisms and solutions to Immune effector Cell-Associated Hematotoxicity (ICAHT) - a major contributor to long term morbidity and mortality following CAR therapy. About 20–40% of the patients develop ICAHT of grade 3 or above, wi...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer
2026-04-01
|
| Edice: | Annals of Hematology |
| Témata: | |
| On-line přístup: | https://doi.org/10.1007/s00277-026-06982-6 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|